Sun Pharma Surges to 52-Week High on South Africa Drug Approval Sun Pharmaceutical Industries Ltd. (Sun Pharma) experienced a significant stock surge, reaching a 52-week high of Rs 1,962.70 on the National Stock Exchange (NSE) on Wednesday. The sharp rise followed the approval of its generic diabetes drug by South Africa’s health regulator, the South African Health Products Regulatory Authority (SAHPRA). The regulatory green light allows the company to manufacture and market the injectable medication for adults with Type 2 diabetes that cannot be managed through diet and exercise alone. The drug, sold as a pre-filled pen in two strengths, is designed for once-a-week use, marking a key milestone in Sun Pharma’s expansion into international markets. The approval is notable as it represents only the second country where Sun Pharma has secured such clearance, with India being the first. Company COO Aalok Shanghvi highlighted the significance of the regulatory nod, stating it underscores the company’s capability to develop complex generic medicines that meet stringent quality standards globally. He emphasized the goal of enhancing access to evidence-based treatments, particularly in regions where healthcare resources are limited. The drug’s approval aligns with South Africa’s growing diabetes prevalence, driven by urbanization and lifestyle changes. The company noted that expanding treatment access is critical in addressing the rising number of cases, which has placed increasing pressure on healthcare systems. Sun Pharma’s strategic focus on such markets reflects its broader efforts to diversify its portfolio and strengthen its global footprint.#south_africa #sun_pharmaceutical_industries_ltd #south_african_health_products_regulatory_authority #aalok_shanghvi #innovacare_lifesciences
